Bioarchitech Ltd

Bioarchitech Ltd from Oxford UK: a small, holding company with an active status, was founded eleven years ago. It employs four people and holds assets of £901,435. The company has a real address, two directors, and one owner. It’s an irregular importer of miscellaneous chemical products, with just one month of imports recorded back in March 2022.

The company operates in the biotechnology industry, focusing on research and experimental development. Its website details two cancer immunotherapy assets, BAV151 and BAR166, designed to treat cancer at every stage. BAV151 is an intravenous viral therapy for metastatic cancer, while BAR166 is an RNA immunotherapeutic for early-stage cancers. The company’s approach involves mining the genetic code of viruses to create multifunctional therapies that both kill cancer cells and induce immunity. The website suggests a focus on innovation and a pipeline of potential treatments.

Financially, Bioarchitech Ltd’s report shows some concerning trends. Cash bank on hand has fallen by a significant 44% to £740,000, and current assets have decreased by 39% to £900,000. While director remuneration has increased slightly by 6.3%, equity has plummeted by 48% to £930,000. It’s a small company, meeting two of three conditions to be classified as such: turnover under £10.2 million, assets under £5.1 million, and fewer than 50 employees. The substantial drop in equity, however, suggests the company is burning through money, perhaps reinvesting heavily in research and development. The lack of an auditor mentioned in the report is likely due to its small size and exemption from an audit. It seems like Bioarchitech is a high-risk, high-reward venture, betting on cutting-edge biotechnology to achieve substantial growth.

Registered in England/Wales under the registration number 08858643, with a registered address at OX3 0SJ, England, Oxford, 64 Arlington Drive, Marston.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.